Keyword Search

By downloading an article in PDF format, you are agreeing to follow our Article Policy.


Use the KEYWORD search located in the top left column to look for keywords, authors, and titles. If you still can't find what you're looking for, please This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Development of a Reference Material for Characterizing Adenovirus Vectors

by Beth Hutchins, PhD
Volume 1, Issue 1 (March 2002)

The development of reference testing reagents has been used successfully in the past to standardize measurements among laboratories, particularly for biological products such as recombinant cytokines. This approach was recommended by many parties with a stake in adenovirus vector delivery in order to address the fact that particle units and infectious units are not standardized in the field. This has made interpretation of preclinical and clinical data, as it relates to the amount of adenovirus vector administered, difficult to compare across the field. An Adenovirus Reference Material is being developed to define the particle unit and infectious unit for adenovirus gene vectors, and create a commonality for comparisons, especially for data related to vector safety...

Citation:
Hutchins B. Development of a Reference Material for Characterizing Adenovirus Vectors. BioProcess J, 2002; 1(1): 25-29.

 
Ex Vivo Activation and Adoptive Transfer of T Cells for Immune Augmentation

by Bruce L. Levine, PhD
Volume 1, Issue 1 (March 2002)

We have developed a procedure for large-scale enrichment, growth and harvesting of T cells suitable for adoptive immunotherapy. In two recently completed clinical trials, we investigated the feasibility of immune reconstitution in patients with HIV infection, or with relapsed/refractory Non-Hodgkin's Lymphoma (NHL) following infusions of autologous activated CD4+ T cells or CD4+/CD8+ T cells. Autologous T cells were activated via CD3/CD28 stimulation, ex vivo, and were then reinfused...

Citation:
Levine BL. Ex Vivo Activation and Adoptive Transfer of T Cells for Immune Augmentation. BioProcess J, 2002; 1(1): 31-37.

 
Development of Capabilities for Small-Scale Virus Fills

by Joseph H. Senesac, Frank Flagge, and Shawn Gallagher
Volume 1, Issue 1 (March 2002)

Introgen Therapeutics has been producing clinical-grade adenoviral vectors in scaled-up processes, in cGMP facilities, for over five years. Semi-automated hand filling, using a Watson-Marlow 505Di/L pump, has been used over this period to fill batch sizes of up to 2 liters of adenovirus. While this procedure has been robust and demonstrated a high level of sterility assurance through regularly scheduled media fill studies and product testing, the firm needed to move to the next level of fill sizes. Anticipating up to 10,000 fills in 3 mL vials, Introgen has worked in collaboration with M&O Perry Corp. to develop an automated fill capability that utilizes the same base procedure but in an automated fashion...

Citation:
Senesac JH, Flagge F, Gallagher S. Development of Capabilities for Small-Scale Virus Fills. BioProcess J, 2002; 1(1): 38-42.

 
Development of a Stable Adenoviral Vector Formulation

by Diana K. Hoganson, Julie C. Ma, Lara Asato, Mike Ong, Marie A. Printz, Bernard G. Huyghe, Barbara A. Sosnowski, PhD, and Mark J. D'Andrea
Volume 1, Issue 1 (March 2002)

A formulation for purified adenoviral vectors was developed that provides stability through freeze-thaw stress and long-term storage at non-frozen temperatures. To evaluate the various test conditions, a panel of stability indicating methods was assembled, which included laser light scattering, HPLC, and transgene expression assays. Preformulation studies were conducted, and the effects of buffer species, pH, cryoprotectants, and salts upon adenoviral vector stability were determined...

Citation:
Hoganson DK, Ma JC, Asato L, Ong M, Printz MA, Huyghe BG, Sosnowski BA, D'Andrea MJ. Development of a Stable Adenoviral Vector Formulation. BioProcess J, 2002; 1(1): 43-48.

 
Local Gene Therapy for Lumbar Spine Fusion

by Jeffrey C. Marx, PhD
Volume 1, Issue 1 (March 2002)

In orthopedic procedures, there is a need to form new bone to repair and fill defects arising from either trauma or degenerative disease. The current standard treatment utilizes an autograft, usually from the iliac crest, which results in a second surgical site, weakness in the harvest or donor harvest area, and additional patient morbidity. The goal of our research is to employ a local, ex vivo, gene therapy to obviate the need for autograft in spine fusion procedures. The LIM Mineralization Protein (LMP-1) is a novel intracellular protein capable of inducing bone formation in vitro and in vivo. In this article, I will outline a rapid protocol, whereby buffy coat cells, isolated from autologous peripheral blood, are transduced with an adenoviral vector encoding the LMP-1 gene. These transduced cells are then implanted on a collagen carrier to promote posterolateral arthodesis...

Citation:
Marx JC. Local Gene Therapy for Lumbar Spine Fusion. BioProcess J, 2002; 1(1): 49-54.

 
<< Start < Prev 81 82 83 84 85 86 87 88 89 Next > End >>

Page 88 of 89